US Patent Issued to ProQR Therapeutics II on Aug. 26 for "RNA-editing oligonucleotides for the treatment of usher syndrome" (Dutch Inventors)

ALEXANDRIA, Va., Aug. 26 -- United States Patent no. 12,398,393, issued on Aug. 26, was assigned to ProQR Therapeutics II B.V. (Leiden, Netherlands).

"RNA-editing oligonucleotides for the treatment of usher syndrome" was invented by Lenka Van Sint Fiet (Leiden, Netherlands), Kalyana Chakravarthi Dulla (Leiden, Netherlands) and Jim Swildens (Leiden, Netherlands).

According to the abstract* released by the U.S. Patent & Trademark Office: "The invention relates to RNA editing oligonucleotides that are capable of bringing about specific editing of a target nucleotide (adenosine) in a target RNA molecule in a eukaryotic cell, wherein said oligonucleotide is for use in the treatment of Usher syndrome, and more preferably for the deamination of ...